Terminated × Anemia, Refractory, with Excess of Blasts × Clear all
NCT04083170 2025-01-01

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Fred Hutchinson Cancer Center

Phase 2 Terminated
1 enrolled 11 charts
NCT00119366 2022-12-12

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 2 Terminated
18 enrolled 18 charts
NCT02231853 2019-12-17

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
12 enrolled
NCT02728700 2018-09-12

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

Stanford University

Phase 1 Terminated
1 enrolled
NCT00295880 2017-12-28

Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
12 enrolled 14 charts
NCT00818649 2017-12-28

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
16 enrolled 7 charts
NCT00376519 2017-12-02

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
3 enrolled
NCT00281879 2017-09-27

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
200 enrolled 11 charts
NCT00719849 2017-06-14

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
13 enrolled 24 charts
NCT00255684 2016-11-03

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

University of Rochester

Phase NA Terminated
16 enrolled 6 charts
NCT00963495 2015-06-22

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

University Health Network, Toronto

Phase 1 Terminated
11 enrolled
NCT00594308 2014-10-06

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Indiana University

Phase NA Terminated
10 enrolled 11 charts
NCT01500161 2013-11-25

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Texas Oncology Cancer Center

Phase 2 Terminated
1 enrolled
NCT00514722 2013-08-14

Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies

University of California, San Francisco

Phase NA Terminated
4 enrolled
NCT00513318 2013-08-02

Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies

University of California, San Francisco

Terminated
15 enrolled
NCT00393380 2013-04-29

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

The Emmes Company, LLC

Phase 2 Terminated
13 enrolled 14 charts
NCT00006220 2013-02-06

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy

Washington University School of Medicine

Phase 1/2 Terminated
5 enrolled
NCT00005641 2012-12-11

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
NCT00004058 2010-01-26

12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

Rutgers, The State University of New Jersey

Phase 1 Terminated